A24 Glanders and melioidosis

Name of the Condition

• Glanders and melioidosis

Summary

Glanders and melioidosis are infectious diseases caused by the bacterium Burkholderia mallei (glanders) and Burkholderia pseudomallei (melioidosis), respectively. Both conditions can affect multiple organ systems and are characterized by fever, respiratory symptoms, and potential for severe systemic illness. Glanders primarily affects horses and other equines but can transmit to humans, while melioidosis is endemic in tropical regions and often linked to environmental exposure.

Causes

Glanders is caused by Burkholderia mallei, a gram-negative bacterium, typically transmitted through direct contact with infected animals or their secretions. Melioidosis is caused by Burkholderia pseudomallei, which is found in soil and water, and infection occurs through inhalation, ingestion, or skin inoculation of contaminated material. Both bacteria can cause localized or disseminated disease depending on the route of exposure.

Risk Factors

• Occupational exposure to infected animals (e.g., veterinarians, farmers) for glanders.
• Residing in or traveling to tropical regions where Burkholderia pseudomallei is endemic (e.g., Southeast Asia, northern Australia) for melioidosis.
• Underlying conditions such as diabetes, chronic lung disease, or immunosuppression, which increase susceptibility to severe melioidosis.
• Direct contact with contaminated soil or water in endemic areas.

Symptoms

• Fever and chills
• Cough, chest pain, or respiratory distress
• Skin lesions (nodules, ulcers, or abscesses)
• Muscle and joint pain
• Headache and fatigue
• Gastrointestinal symptoms (nausea, vomiting, diarrhea)
• In severe cases, sepsis or organ failure (e.g., lung, liver, or spleen involvement).

Diagnosis

Diagnosis involves clinical evaluation, laboratory testing, and imaging. Cultures of blood, sputum, or wound samples may identify Burkholderia species. Molecular tests (e.g., PCR) can confirm the presence of specific bacteria. Imaging (e.g., chest X-rays or CT scans) may reveal pulmonary or systemic involvement. Serological tests are available but may have limited sensitivity.

Treatment Options

• Antibiotics: Intravenous antibiotics (e.g., ceftazidime, meropenem) are used initially, followed by oral therapy (e.g., trimethoprim-sulfamethoxazole) for extended periods (months) to prevent relapse.
• Supportive care: Management of sepsis, organ dysfunction, or respiratory failure may require intensive care support.
• Surgical intervention: Drainage of abscesses or debridement of infected tissues may be necessary in some cases.

Prognosis and Follow-Up

Prognosis depends on the severity of infection, timeliness of treatment, and underlying health. Early diagnosis and appropriate antibiotic therapy improve outcomes, but relapse can occur, especially with melioidosis. Follow-up includes monitoring for recurrence, repeat cultures, and long-term antibiotic adherence. Chronic or disseminated disease may require ongoing surveillance.

Complications

• Respiratory failure or pneumonia
• Sepsis and multi-organ dysfunction
• Chronic abscess formation or osteomyelitis
• Neurological involvement (e.g., encephalitis)
• Death in severe or untreated cases.

Lifestyle & Prevention

• Avoid contact with infected animals or their secretions (glanders).
• Use protective gear (e.g., gloves, masks) when handling soil or water in endemic regions (melioidosis).
• Practice good wound care to prevent skin inoculation.
• Ensure safe drinking water and avoid consumption of contaminated food in high-risk areas.
• Immunocompromised individuals should take extra precautions in endemic zones.

When to Seek Professional Help

Seek immediate medical attention if you experience fever, respiratory symptoms, or skin lesions after potential exposure to Burkholderia (e.g., travel to endemic areas, animal contact). Prompt treatment is critical to reduce severe complications.

Tips for Medical Coders

• Code A24 encompasses both glanders (Burkholderia mallei) and melioidosis (Burkholderia pseudomallei); specify the causative organism in clinical documentation when possible.
• Document the site of infection (e.g., respiratory, skin, sepsis) and any systemic involvement to support coding accuracy.
• Note acute versus chronic presentations, as this may impact coding and treatment planning.
• Ensure laboratory confirmation (e.g., culture, PCR) is documented to validate the diagnosis for coding purposes.